

## List of Contents

<i>Title</i>	<i>Page</i>
<b>List of Abbreviations</b>	<b>II</b>
<b>List of Figures</b>	<b>IV</b>
<b>List of Tables</b>	<b>VI</b>
<b>Introduction</b>	<b>1</b>
<b>Aim of the Work</b>	<b>4</b>
<b>Review of Literature</b>	
<b>Chapter (1): Nonalcoholic fatty liver disease</b>	<b>5</b>
<b>Chapter (2): Cytokeratin</b>	<b>69</b>
<b>Chapter (3): Monoclonal antibodies</b>	<b>89</b>
<b>Patients and Methods</b>	<b>93</b>
<b>Results</b>	<b>99</b>
<b>Discussion</b>	<b>123</b>
<b>Summary and Conclusion</b>	<b>129</b>
<b>Recommendations</b>	<b>131</b>
<b>References</b>	<b>132</b>
<b>Arabic Summary</b>	<b>—</b>

## *List of Abbreviations*

<b>ALT:</b>	Alanine transaminase.
<b>AST:</b>	Aspartate transaminase.
<b>Asp:</b>	Aspartate
<b>BMI:</b>	Body mass index.
<b>BUN:</b>	Blood urea nitrogen.
<b>CBC:</b>	Complete blood count.
<b>CK18:</b>	Cytokeratin 18 Fragments
<b>CT:</b>	Computerized Tomography
<b>FBS:</b>	Fasting blood sugar
<b>HBV:</b>	Hepatitis B virus.
<b>HBA1C:</b>	hemoglobin A 1 C (Glycohemaglobin)
<b>HCC:</b>	Hepatocellular carcinoma.
<b>HCV:</b>	Hepatitis C virus.
<b>HELLP:</b>	<b>H</b> emolysis, <b>E</b> levated <b>L</b> iver enzymes, <b>L</b> ow <b>P</b> latelet count
<b>HTN:</b>	Hypertension.
<b>HU:</b>	Hounsfield unit
<b>IDDM:</b>	Insulin dependent Diabetes Mellitus.

## **List of Abbreviations** (Cont.)

<b>INR:</b>	International normalized ratio.
<b>kDa:</b>	atomic mass unit = kilo dalton
<b>LDL:</b>	Low density lipoprotein.
<b>MAB:</b>	Monoclonal antibodies
<b>MR:</b>	Magnetic Resonance.
<b>NAFL:</b>	Nonalcoholic Fatty Liver
<b>NAFLD:</b>	Nonalcoholic Fatty Liver Disease
<b>NAS:</b>	NAFLD Activity Score
<b>NASH:</b>	Nonalcoholic Steatohepatitis
<b>PIVENS:</b>	Pioglitazone versus Vitamin E versus Placebo for the Treatment of Non-diabetic patients with Nonalcoholic steatohepatitis
<b>PT:</b>	Prothrombin time.
<b>PTT:</b>	Partial thromboplastin time.
<b>SD:</b>	Standard deviation.
<b>T2DM:</b>	Type 2 Diabetes Mellitus
<b>TG:</b>	Triglycerides
<b>U/S:</b>	Ultrasound

## List of Figures

<b>Fig. No.</b>	<b>Title</b>	<b>Page No.</b>
1	Prevalence in general population	9
2	incidence of obesity in different age	11
3	effect of insulin resistance on fat metabolism	14
4	effect of obesity and diabetes on the liver	18
5	Molecules involved in the developing steatosis.	20
6	NAFLD progression	23
7	effect of Kupffer cell in NAFLD	25
8	the pathological feature of NAFLD	30
9	metabolic syndrome pathogenesis	47
10	diagnostic approach to NAFLD	49
11	pathway to liver biopsy	53
12	normal sonographic criteria of the liver	56
13	CT without contrast normal difference in the liver.	57
14	unenhanced CT of fatty liver	58
15	Molecular structure of CKs	70
16	Cytoskeleton of epithelial cells	76
17	difference between apoptosis and necrosis	77
18	cytokeratin release in apoptosis and necrosis.	78
19	sites of cleavage of cytokeratin	79
20	CK18 and M30-antibody	80
21	Chronic alcohol abuse effect	84

<b>Fig. No.</b>	<b>Title</b>	<b>Page No.</b>
22	Monoclonal antibody synthesis	90
23	Comparison between groups as regards DM	105
24	Comparison between groups as regards Fasting Glucose	106
25	Comparison between groups as regards Glycohemaglobin	107
26	Comparison between groups as regards HTN	108
27	Comparison between groups as regards dyslipidemia	109
28	Comparison between groups as regards HCV	110
29	Comparison between both groups as regards steatosis	111
30	Comparison between both groups as regards lobular inflammation	112
31	Comparison between both groups as regards ballooning of hepatocytes	113
32	Comparison between both groups as regards fibrosis	114
33	Comparison between both groups as regards Mallory bodies	115
34	Correlation between presence of HCV and level of CK18	119
35	ROC curve	121
36	Logistic Regression test	122

## List of Tables

Table No.	Title	Page No.
1	Diagnostic criteria for metabolic syndrome	48
2	Therapeutic approaches for NAFLD	67
3	types of cytokeratin and its origin	72
4	Cytokeratin expression in tumor	73
5	Comparison between groups as regards gender	103
6	Comparison between groups as regards age	103
7	Comparison between groups as regards body mass index	104
8	Comparison between groups as regards DM	104
9	Comparison between groups as regards Fasting Glucose	106
10	Comparison between groups as regards Glycosylated haemoglobin	107
11	Comparison between groups as regards HTN	108
12	Comparison between groups as regards dyslipidemia	109
13	Comparison between groups as regards HCV	110
14	Comparison between both groups as regards steatosis	111
15	Comparison between both groups as regards lobular inflammation	112

<b>Table No.</b>	<b>Title</b>	<b>Page No.</b>
16	Comparison between both groups as regards ballooning of hepatocytes	113
17	Comparison between both groups as regards fibrosis	114
18	Comparison between both groups as regards Mallory bodies	115
19	showing comparison between parameter as regard P value and post Hoc test	116
20	Correlation between CK18 and gender	117
21	Correlation between Dyslipidemia and level of CK18	117
22	Correlation between CK18 and DM	117
23	Correlation between both groups as regards NAS score	118
24	Correlation between CK18 and HCV	119
25	Correlation between all parameter and CK18	120
26	showing diagnostic performance of CK18 in diagnosis of NASH	121

# **Role of cytokeratin 18 in early detection of liver fibrosis in patients of nonalcoholic steatohepatitis in comparison with liver biopsy**

**Thesis**

**Submitted for Partial Fulfillment of Master Degree in  
Internal Medicine**

**By**

***Mohamed Gamal Esmael Mohamed Yossef***  
*MB.B.Ch. Faculty of Medicine*  
*Ain Shams University*

**Under Supervision of**

**Prof. Dr. Mohsen Mostafa Maher**

Professor of Internal Medicine and Gastroenterology  
Faculty of Medicine, Ain Shams University

**Assistant Prof. Dr. Wesam Ahmed Ibrahim**

Assistant Professor of Internal Medicine and Gastroenterology  
Faculty of Medicine, Ain Shams University

**Dr. Shereen Abou Bakr Abdel Rahman**

Lecturer of Internal Medicine and Gastroenterology  
Faculty of Medicine, Ain Shams University

**Faculty of Medicine  
Ain Shams University  
2013**



**دور الكراتين الخلوى 18 في الكشف المبكر عن تليف الكبد في  
المرضى الذين يعانون من التهاب الكبد الدهنى الغير كحولي بالمقارنة  
مع عينة الكبد**

رسالة  
المقدمة للحصول على ماجستير طب الباطنة العامة

بواسطة  
محمد جمال اسماعيل محمد يوسف  
بكالوريوس طب وجراحة  
جامعة عين شمس

تحت الإشراف  
الأستاذ الدكتور/ محسن مصطفى ماهر  
أستاذ الباطنة العامة وأمراض الجهاز الهضمي والكبد  
كلية الطب، جامعة عين شمس

الأستاذ المساعد الدكتورة/ وسام أحمد إبراهيم  
أستاذ مساعد في الباطنة العامة و أمراض الجهاز الهضمي والكبد  
كلية الطب، جامعة عين شمس

الدكتورة/ شيرين ابو بكر عبد الرحمن  
مدرس في الباطنة العامة و أمراض الجهاز الهضمي والكبد  
كلية الطب، جامعة عين شمس

كلية الطب  
جامعة عين شمس 2013



## Acknowledgement

First of all, all gratitude is due to **Allah** almighty for blessing this work, until it has reached its end, as apart of his generous help, throughout my life.

Really I can hardly find the words to express my gratitude to **Prof. Dr. Mohsen Maher** professor of internal medicine, Faculty of Medicine Ain Shams University, for his supervision, continuous help, encouragement throughout this work and tremendous effort he has done in the meticulous revision of the whole work. It is a great honor to work under his guidance and supervision.

I would like to express my thanks and appreciation to **Prof. Dr. Wesam Ahmed Ibrahim** assistant Professor of Internal Medicine Faculty of Medicine Ain Shams University, for his guidance and sincere supervision of this work.

I am also indebted to **Lecturer Dr. Shereen Abou Bakr** of Internal Medicine Faculty of Medicine Ain Shams University, for her guidance, continuous assistance and sincere supervision of this work.

I can not forget the great help of staff of pathology department with special thanks to **Prof. Dr. Mohamoud Reda** Professor of pathology manager of Ain Shams specialist hospital pathology department for giving me permission to data, samples.

Last but not least I dedicate this work to my **Father, Mother and wife** who have a great favour on me. Also I dedicate it to my **brother, sister** whom without their sincere emotional support and pushing me forward this work would not have ever been completed.



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لَسْبَقَ أَنْتَ لَنَا  
إِلَٰهًا مَا عَلِمْنَا أَنَّكَ أَنْتَ  
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

## Introduction

Fatty liver is the accumulation of triglycerides and other fats in the liver cells. The amount of fatty acid in the liver depends on the balance between the processes of delivery and removal. NAFLD encompasses a wide spectrum of conditions associated with over accumulation of fat in the liver ranging from nonalcoholic fatty liver disease (NAFLD) or simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis. (*Bacon et al., 2004*)

Although Nonalcoholic fatty liver disease (NAFLD) typically follows a benign non progressive clinical course, NASH is a potentially serious condition; as many as 25% of patients may progress to cirrhosis and experience complications of portal hypertension, liver failure, and hepato-cellular carcinoma. (*Larter et al., 2006*)

NAFLD is the most common form of chronic liver disease in both children and adults and threatens to become a serious public health problem. The prevalence of NAFLD and NASH are higher than previously estimated among predominantly middle-aged patients. Although all ethnicities

are affected and patients have varying degrees of insulin sensitivity, Diabetic patients appear to be at the greatest risk for both NAFLD and NASH. (*Browning et al., 2004*)

Other causes of NASH include obesity, metabolic syndrome, Wilson's disease, celiac disease high cholesterol and high triglycerides, rapid weight loss and malnutrition, some medications such as tamoxifen, amiodarone and methotrexate. (*Pagano et al., 2002*)

At present, the available noninvasive tests to distinguish NASH from NAFLD include clinical signs and symptoms, routine laboratory and radiological imaging tests, and combinations of clinical and blood test results. Unfortunately, these tests are of limited use, and liver biopsy remains the only reliable way of diagnosing NASH and grading the severity of liver damage therefore, an urgent need to develop and validate a simple, reproducible, noninvasive test that both accurately distinguishes NASH from NAFLD and determines the stage and grade of the disease (*Sanyal, 2002*)

Hepatocyte apoptosis, a highly organized and genetically controlled form of cell death, may play an important role in liver injury and disease progression in NAFLD. Increase in hepatocyte cell death by apoptosis is typically present in

humans with NASH as well as animal models of NASH but absent in those with NAFLD. A central consequence of the apoptotic process is the activation of the effector caspases (mainly caspase-3), which cleave a number of different substrates inside the cell—including cytokeratin 18 (CK-18), the major intermediate filament protein in the liver—resulting in the characteristic morphologic changes of apoptosis. (*Guicciardi et al., 2005*)

It was recently demonstrated that plasma cytokeratin 18 (CK-18) fragment levels correlate with the magnitude of hepatocyte apoptosis and independently predict the presence of NASH. Determination of CK-18 fragments in the blood predicts histological NASH and severity of disease in a large, diverse population of patients with biopsy-proven NAFLD, supporting the potential usefulness of this test in clinical practice. (*Linder et al., 2009*)

## **Aim of the Work**

Evaluation of the role of cytokeratin 18 in early detection of liver fibrosis in patients of nonalcoholic steatohepatitis in comparison with liver biopsy